Active substance
Clomiphene
- US FDA 9
- US price lines 3
- Safety 1
US FDA United States — FDA approvals (Drugs@FDA)
| Product | Strength | Form · route | Applicant | Status | First approved |
|---|---|---|---|---|---|
| MILOPHENE | 50MG | tablet · oral | GRANATA BIO CORP | Prescription | 20 Dec 1988 |
| CLOMID | 50MG | tablet · oral | COSETTE | Prescription | 30 Aug 1999 |
| CLOMIPHENE CITRATE | 50MG | tablet · oral | APPCO | Prescription | 8 Nov 2024 |
| CLOMIPHENE CITRATE | 50MG | tablet · oral | RUBICON RESEARCH | Prescription | 12 Nov 2024 |
| CLOMIPHENE CITRATE | 50MG | tablet · oral | ACCORD HLTHCARE | Prescription | 3 Oct 2025 |
| CLOMIPHENE CITRATE | 50MG | tablet · oral | NOVITIUM PHARMA | Prescription | 17 Oct 2025 |
| CLOMIPHENE CITRATE | 50MG | tablet · oral | ASCENT PHARMS INC | Prescription | 15 May 2026 |
| CLOMID | 50MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** | tablet · oral | SANOFI AVENTIS US | Discontinued | 1 Feb 1967 |
| SEROPHENE | 50MG | tablet · oral | EMD SERONO | Discontinued | 22 Mar 1982 |
Prices — United States and England
| Source | Product as listed | Price | Unit / pack | Date |
|---|---|---|---|---|
| US NADAC | CLOMID 50 MG TABLET | $16.74327 | per EA | 12 Jun 2026 |
| US NADAC | CLOMIPHENE CITRATE 50 MG TAB | $4.20523 | per EA | 23 Sep 2026 |
| US NADAC | MILOPHENE 50 MG TAB | $4.20523 | per EA | 23 Sep 2026 |
NADAC: average price US retail pharmacies pay to buy the medicine. NHS Drug Tariff Part VIIIA: basic price reimbursed to pharmacies in England and Wales.
Safety signals and safety-related labeling changes
- US FDA 18 Dec 2017 CLOMID — safety-related labeling change
Labeling sections changed: Warnings and Precautions; Adverse Reactions
Values as published by each source: SFDA human drug list (4-2026, as published by the Council of Health Insurance; indications from the CHI Daman Drug Formulary), Drugs@FDA, EMA medicines data, Health Canada Drug Product Database (Open Government Licence – Canada), CMS NADAC, NHS Drug Tariff Part VIIIA (NHSBSA Copyright, Open Government Licence v3.0), WHO Model List of Essential Medicines (CC BY 3.0 IGO; regrouped by active substance, not created by WHO), EMA PRAC, US FDA safety-related labeling changes and MHRA Drug Safety Update (Open Government Licence v3.0). Sources and reuse. Not a substitute for the official registers or the product information.